Journal of Clinical Oncology, Vol 25, No 10 (April 1), 2007: pp. 1196-1208
© 2007 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2006.07.8626
Molecular Profiling Identifies Prognostic Subgroups of Pediatric Glioblastoma and Shows Increased YB-1 Expression in Tumors
Damien Faury,
André Nantel,
Sandra E. Dunn,
Marie-Christine Guiot,
Takrima Haque,
Péter Hauser,
Miklós Garami,
László Bognár,
Zoltán Hanzély,
Pawel P. Liberski,
Enrique Lopez-Aguilar,
Elvis T. Valera,
Luis G. Tone,
Anne-Sophie Carret,
Rolando F. Del Maestro,
Martin Gleave,
Jose-Luis Montes,
Torsten Pietsch,
Stephen Albrecht,
Nada Jabado
From the Division of Hemato-Oncology, Department of Pediatrics; Department of Pathology, Montréal Children's Hospital Research Institute; Division of Neuro-Surgery, Montréal Children's Hospital; Division of Neuro-Surgery and the Brain Tumor Research Center, Montréal Neurological Institute, McGill University Health Center; Biotechnology Research Institute, National Research Council of Canada, Montréal; Laboratory for Oncogenomic Research, Department of Pediatrics, British Columbia Research Institute for Children's and Women's Health; Department of Surgery, Prostate Cancer Center, Jack Bell Research Laboratories, Vancouver; Second Department of Pediatrics, Semmelweis University; Division of Neuro-surgery, Division of Pathology, National Institute of Neurosurgery, Budapest, Hungary; Department of Neuropathology, Medical University of Lodz, Lodz, Poland; Oncology Department, Pediatrics Hospital, Centro Medico Nacional Siglo XXI, Mexico City, Mexico; Department of Pediatrics, University Hospital, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, São Paulo, Brazil; Institut of Neuropathology, University of Bonn, Bonn, Germany
Address reprint requests to Nada Jabado, MD, PhD, Montreal Children's Hospital Research Institute, 4060 Ste Catherine West, PT-239, Montreal, Quebec, Canada H3Z 2Z3; e-mail: nada.jabado{at}mcgill.ca
Purpose Pediatric glioblastoma (pGBM) is a rare, but devastating brain tumor. In contrast to GBM in adults (aGBM), little is known about the mechanisms underlying its development. Our aim is to gain insight into the molecular pathways of pGBM.
Materials and Methods Thirty-two pGBM and seven aGBM samples were investigated using biochemical and transcriptional profiling. Ras and Akt pathway activation was assessed through the phosphorylation of downstream effectors, and gene expression profiles were generated using the University Health Network Human 19K cDNA arrays. Results were validated using real-time polymerase chain reaction and immunohistochemistry and compared with existing data sets on aGBM.
Results There are at least two subsets of pGBM. One subset, associated with Ras and Akt pathway activation, has very poor prognosis and exhibits increased expression of genes related to proliferation and to a neural stem-cell phenotype, similar to findings in aggressive aGBM. This subset was still molecularly distinguishable from aGBM after unsupervised and supervised analysis of expression profiles. A second subset, with better prognosis, is not associated with activation of Akt and Ras pathways, may originate from astroglial progenitors, and does not express gene signatures and markers shown to be associated with long-term survival in aGBM. Both subsets of pGBM show overexpression of Y-box-protein-1 that may help drive oncogenesis in this tumor.
Conclusion Our work, the first study of gene expression profiles in pGBM, provides valuable insight into active pathways and targets in a cancer with minimal survival, and suggests that these tumors cannot be understood exclusively through studies of aGBM.
Supported by the Canadian Institute of Health Research and the Penny Cole Foundation (N.J.), an NRC Genome Health Initiative grant (A.N.), the Hungarian Scientific Research Fund (O.T.K.A.) Contract No. T-04639, and the National Research and Development Fund (N.K.F.P.) Contract No. 1A/002/2004 (P.H., M.G., L.B., Z.H.). N.J. is the recipient of a Chercheur Boursier Award from Fonds de la Recherche en Sante du Québec.
D.F. and A.N. contributed equally to this article.
This is National Research Council publication No. 47482.
Terms in blue are defined in the glossary, found at the end of this article and online at www.jco.org.
Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike Complore Connotea Del.icio.us Digg Facebook Reddit Technorati Twitter What's this?
This article has been cited by other articles:

|
 |

|
 |
 
H.-Q. Qu, K. Jacob, S. Fatet, B. Ge, D. Barnett, O. Delattre, D. Faury, A. Montpetit, L. Solomon, P. Hauser, et al.
Genome-wide profiling using single-nucleotide polymorphism arrays identifies novel chromosomal imbalances in pediatric glioblastomas
Neuro Oncology,
February 1, 2010;
12(2):
153 - 163.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
O. Gluz, K. Mengele, M. Schmitt, R. Kates, R. Diallo-Danebrock, F. Neff, H.-D. Royer, N. Eckstein, S. Mohrmann, E. Ting, et al.
Y-Box-Binding Protein YB-1 Identifies High-Risk Patients With Primary Breast Cancer Benefiting From Rapidly Cycled Tandem High-Dose Adjuvant Chemotherapy
J. Clin. Oncol.,
December 20, 2009;
27(36):
6144 - 6151.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Gao, A. Fotovati, C. Lee, M. Wang, G. Cote, E. Guns, B. Toyota, D. Faury, N. Jabado, and S. E. Dunn
Inhibition of Y-box binding protein-1 slows the growth of glioblastoma multiforme and sensitizes to temozolomide independent O6-methylguanine-DNA methyltransferase
Mol. Cancer Ther.,
December 1, 2009;
8(12):
3276 - 3284.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Pfister, C. Hartmann, and A. Korshunov
Histology and Molecular Pathology of Pediatric Brain Tumors
J Child Neurol,
November 1, 2009;
24(11):
1375 - 1386.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
E. De Carli, X. Wang, S. Puget, F. Ducray, Y. Marie, M. Sanson, Z. Reitman, and H. Yan
IDH1 and IDH2 mutations in gliomas.
N. Engl. J. Med.,
May 21, 2009;
360(21):
2248 - 2248.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Garcia-Crespo, E. Knock, N. Jabado, and R. Rozen
Intestinal Neoplasia Induced by Low Dietary Folate Is Associated with Altered Tumor Expression Profiles and Decreased Apoptosis in Mouse Normal Intestine
J. Nutr.,
March 1, 2009;
139(3):
488 - 494.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Broniscer, S. J. Baker, C. F. Stewart, T. E. Merchant, F. H. Laningham, P. Schaiquevich, M. Kocak, E. B. Morris, R. Endersby, D. W. Ellison, et al.
Phase I and Pharmacokinetic Studies of Erlotinib Administered Concurrently with Radiotherapy for Children, Adolescents, and Young Adults with High-Grade Glioma
Clin. Cancer Res.,
January 15, 2009;
15(2):
701 - 707.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Martinez-Cardus, E. Martinez-Balibrea, E. Bandres, R. Malumbres, A. Gines, J. L. Manzano, M. Taron, J. Garcia-Foncillas, and A. Abad
Pharmacogenomic approach for the identification of novel determinants of acquired resistance to oxaliplatin in colorectal cancer
Mol. Cancer Ther.,
January 1, 2009;
8(1):
194 - 202.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. F. Pollack
Diagnostic and Therapeutic Stratification of Childhood Brain Tumors: Implications for Translational Research
J Child Neurol,
October 1, 2008;
23(10):
1179 - 1185.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Fujii, A. Kawahara, Y. Basaki, S. Hattori, K. Nakashima, K. Nakano, K. Shirouzu, K. Kohno, T. Yanagawa, H. Yamana, et al.
Expression of HER2 and Estrogen Receptor {alpha} Depends upon Nuclear Localization of Y-Box Binding Protein-1 in Human Breast Cancers
Cancer Res.,
March 1, 2008;
68(5):
1504 - 1512.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Haque, D. Faury, S. Albrecht, E. Lopez-Aguilar, P. Hauser, M. Garami, Z. Hanzely, L. Bognar, R. F. Del Maestro, J. Atkinson, et al.
Gene Expression Profiling from Formalin-Fixed Paraffin-Embedded Tumors of Pediatric Glioblastoma
Clin. Cancer Res.,
November 1, 2007;
13(21):
6284 - 6292.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. To, Y. Zhao, H. Jiang, K. Hu, M. Wang, J. Wu, C. Lee, D. W. Yokom, A. L. Stratford, U. Klinge, et al.
The Phosphoinositide-Dependent Kinase-1 Inhibitor 2-Amino-N-[4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-acetamide (OSU-03012) Prevents Y-Box Binding Protein-1 from Inducing Epidermal Growth Factor Receptor
Mol. Pharmacol.,
September 1, 2007;
72(3):
641 - 652.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|